🚨Arizona Corrections Department Seeks Import of Controlled Substances
Arizona Department of Corrections has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More🏥Proposed Changes to National Medical Support Notice for Businesses
The Office of Child Support Services (OCSS) (Services), Administration for Children and Families (ACF) is requesting the Office of Management and Budget (OMB) to approve the National Medical Support Notice (NMSN) Part A with minor changes, for an additional 3 years. The current OMB approval expires on November 30, 2025. To allow states to program the changes to the proposed NMSN Part A, OCSS requests that the current NMSN Part A be extended 1 year.
Learn More📋CMS Notice on Information Collection Activities and Public Comment
The Centers for Medicare & Medicaid Services (CMS) is announcing an opportunity for the public to comment on CMS' intention to collect information from the public. Under the Paperwork Reduction Act of 1995 (PRA), federal agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension or reinstatement of an existing collection of information, and to allow a second opportunity for public comment on the notice. Interested persons are invited to send comments regarding the burden estimate or any other aspect of this collection of information, including the necessity and utility of the proposed information collection for the proper performance of the agency's functions, the accuracy of the estimated burden, ways to enhance the quality, utility, and clarity of the information to be collected, and the use of automated collection techniques or other forms of information technology to minimize the information collection burden.
Learn More📋HRSA Uniform Data System Reporting Requirements and Business Implications
In compliance with the Paperwork Reduction Act of 1995, HRSA submitted an Information Collection Request (ICR) to the Office of Management and Budget (OMB) for review and approval. Comments submitted during the first public review of this ICR will be provided to OMB. OMB will accept further comments from the public during the review and approval period. OMB may act on HRSA's ICR only after the 30-day comment period for this notice has closed.
Learn More🏥Joint Commission Approved for Hospital Accreditation by CMS
This final notice announces our decision to approve The Joint Commission for continued CMS-recognition as a national accrediting organization for hospitals that wish to participate in the Medicare or Medicaid programs.
Learn More💊FDA Notice on BREYANZI Regulatory Review Period and Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for BREYANZI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More🏥VA Proposes Environmental Impact Statement for Reno Medical Center Relocation
This Notice provides information to Federal, state, and local agencies; Native American tribes; and other interested persons regarding VA's intent to prepare a Programmatic EIS (PEIS) to evaluate the potential environmental impacts for the proposed relocation of the VA Sierra Nevada Health Care System (VASNHCS) Ioannis A. Lougaris VA Medical Center (Reno VAMC) services and facilities in Reno, Nevada. Programmatic National Environmental Policy Act (NEPA) documents are used to assess the environmental impacts of proposed policies, plans, programs, or projects for which subsequent actions will be implemented based on the programmatic analyses, providing the foundation for subsequent additional analysis of specific actions that "tier" from the programmatic document. Tiering allows an agency to eliminate repetitive discussions of the same issues, focus on the actual issues ripe for decision, and exclude from consideration issues already decided or not yet ripe for environmental review. Programmatic NEPA analysis is appropriate in cases where an agency is adopting a large multi-phased program, plans or suite of projects, allowing an agency to make informed decisions timed to coincide with meaningful points in agency planning and decision making. Such is the case with the proposed relocation of the VASNHCS Reno VAMC services and facilities in Reno, Nevada (i.e., project specific siting/construction/ operation of necessary services and supporting facilities, leasing needs, and site opportunities). The analyses for these actions will be broadly discussed in the programmatic document (PEIS) and the specific analyses deferred to the subsequent tiered NEPA document(s) when ripe for environmental review.
Learn More💊FDA Determines Regulatory Review Period for ZILBRYSQ Patent Extension
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ZILBRYSQ and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human drug product.
Learn More💊FDA Notice on ALTUVIIIO Patent Extension and Review Period
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ALTUVIIIO and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More💊FDA Patent Extension Notice for COLUMVI
The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for COLUMVI and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of applications to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.
Learn More